<![CDATA[Why High-Risk Stage I NSCLC Needs a Post-Surgical Vaccine Option]]>

personalized mRNA vaccineNeutral

AI Analysis

Summary

Dr. Dan Costin discusses the rationale for testing a personalized mRNA vaccine as a post-surgical treatment option for high-risk stage I non-small cell lung cancer patients following tumor resection.

Importance:2/10

Sentiment:

0.00

mRNA vaccineNSCLCpost-surgicalpersonalized medicinestage I

Related Companies

$OPTN

Read the original article

Published by Cancer Network on October 5, 2026 8:00 PM

Read Original